SLRX Salarius Pharmaceuticals, Inc. Projected Sales Volume

Salarius Pharmaceuticals Inc - graphic logo of issuer SLRX

Salarius Pharmaceuticals relies on grants to develop epigenetic treatments for rare tumors, while FDA orphan drug status ensures a future monopoly. The company's future sales metric demonstrates market equilibrium, where 0.00 serves as the final level mark. Strategic alliances with oncology centers are expanding pediatric cancer therapies, significantly enhancing the company's investment attractiveness for future merger and acquisition deals.

Company Projected Revenue: Salarius Pharma (SLRX) for 07/04/2022 - 01/08/2026

Financial and market metric breakdowns for Salarius (SLRX)

Basic company analysis:salariuspharma.com SLRX
Signature product of Salarius Pharmaceuticals Inc

An investment audit of the issuer requires a thorough assessment of future cash flow potential prior to asset acquisition. This metric aggregates market expectations for total commercial revenues, measuring the liquidity and resilience of the business model. For Salarius Pharmaceuticals (SLRX), this calculation reflects the commercial success of genetic research in the therapy of rare oncological diseases. Stability or stagnation in the current sales forecast level signals the degree of market confidence in bringing drugs to the monetization stage.

Analysis of competing companies

Projected Sales Volume ONC|HALO (Halozyme) - Company Future Revenue|Projected Sales Volume RVMD (revmed.com)|Company Future Sales Ascentage (AAPG)|CGON: Company Future Sales Volume|Company Expected Sales Volume UroGen Pharma Ltd.|BCAX: Projected Sales Volume|PSNL - Company Future Sales|ERAS (Erasca Oncology) - Projected Sales Volume|Projected Sales Volume Delcath Systems, Inc.|Company Projected Revenue ymabs.com (YMAB)|Company Projected Revenue AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Company Future Sales Volume|Accuray Inc. (ARAY) - Company Expected Sales Volume|SELLAS Life Sciences Group, Inc. - Projected Sales Volume|Company Future Revenue ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Company Projected Revenue|HURA - Company Future Sales|TARA (Protara Therapeutics, Inc.) - Projected Sales Volume|Projected Sales Volume Fate Therapeutics Inc|Projected Sales Volume WHWK|Projected Sales Volume TScan Therapeutics Inc (TCRX)|Company Projected Revenue championsoncology.com CSBR|XBIT - Company Future Sales Volume|CVM - Company Projected Revenue|Company Future Revenue OSTX (OS Therapies)|RADX: Projected Sales Volume|Artiva Biotherapeutics Inc. - Company Future Revenue|ANL (Adlai Nortye) - Projected Sales Volume|Projected Sales Volume verupharma.com|Company Future Sales Volume TPST (tempesttx.com)|Company Future Sales Volume Xilio Therapeutics Inc XLO|Projected Sales Volume RENB (Enochian BioSciences)|Mural Bio - Company Projected Revenue|KAPA - Company Projected Revenue|OnKure Therapeutics (OKUR) - Company Future Sales Volume|GDTC: Projected Sales Volume|Company Expected Sales Volume Curis Corp (CRIS)|APLM (apollomicsinc.com) - Projected Sales Volume|Company Future Sales Volume Tharimmune Corp (THAR)|Projected Sales Volume ADVB|GNPX - Company Expected Sales Volume|Company Projected Revenue calidibio.com CLDI|SBFM - Company Future Sales Volume|XBIO - Company Projected Revenue|Company Expected Sales Volume Kitov Pharma|AON (AONC) - Company Projected Revenue|Company Future Sales Volume BeiGene|Company Projected Revenue checkpointtx.com|Company Revenue Forecast ELEV (Elevation Oncology)|Projected Sales Volume ICAD|Ikena Oncology - Company Revenue Forecast|Company Projected Revenue Notable Labs, Ltd. NTBL|VIRX: Company Revenue Forecast|MOR - Company Projected Revenue|NAYA Bio (NAYA) - Company Future Sales Volume|AAPGV: Projected Sales Volume